Semler Scientific, Inc. is engaged in developing and marketing technology products and services to healthcare providers to combat chronic diseases. The Company's flagship product, QuantaFlo, which is patented and cleared by the United States Food and Drug Administration (FDA), is a rapid point-of-care test that measures arterial blood flow in the extremities. The QuantaFlo test aids in the diagnosis of cardiovascular diseases, such as peripheral arterial disease (PAD), and the Company is seeking a new 510(k) clearance for expanded-indications. QuantaFlo is used by healthcare providers to evaluate their patient's risk of mortality and major adverse cardiovascular events (MACE). QuantaFlo features a sensor clamp that is placed on the toe or finger. A blood flow waveform is instantaneously constructed by its software algorithm. The Company delivers QuantaFlo directly to its customers. The Company also invests in bitcoin and has adopted Bitcoin as its primary treasury asset.
成長中
同社は成長フェーズにあり、最新の年間収益はUSD 56.29Mに達しています。
高い利益成長
同社の純利益は業界をリードしており、最新の年間純利益はUSD 56.29Mです。
割安
同社の最新のPEは3.65で、過去3年間の水準と比較して安値圏にあります。
機関投資家の売り越し
最新の機関投資家の保有株数は10.05M株で、前四半期比で27.59%減少しています。
HACAXが保有
スター投資家HACAXは本銘柄を31.00株保有しています。
市場活動が低調
同社への投資家の関心は低下しており、20日間の売買回転率は0.24です。